Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT-1014-6470 in vitro and in vivo.

Anliker-Ort, Marion; Dingemanse, Jasper; Delahaye, Stephane; Janu, Lubos; van den Anker, John; Berger, Benjamin; Kaufmann, Priska

Anliker-Ort, Marion; Dingemanse, Jasper; Delahaye, Stephane; Janu, Lubos; van den Anker, John; Berger, Benjamin; Kaufmann, Priska.

Afiliación

Anliker-Ort M; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Dingemanse J; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel (UKBB), University of Basel, Basel, Switzerland.
Delahaye S; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Janu L; Department of Preclinical Drug Metabolism and Pharmacokinetics, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
van den Anker J; CEPHA s.r.o., Pilsen, Czech Republic.
Berger B; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel (UKBB), University of Basel, Basel, Switzerland.
Kaufmann P; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.

Clin Transl Sci ; 16(7): 1220-1231, 2023 07.

Article en En | MEDLINE | ID: mdl-37042126

Asunto(s)

Citocromo P-450 CYP3A; Factor Va; Humanos; Masculino; Midazolam/farmacocinética; Citocromo P-450 CYP2C19; Interacciones Farmacológicas; Sistema Enzimático del Citocromo P-450; Omeprazol/farmacocinética

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Factor Va / Citocromo P-450 CYP3A Tipo de estudio: Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Clin Transl Sci Año: 2023 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google